Abstract
Objective To explore the clinical effect of magnesium valproate sustained release tablets combined with olanzapine in treatment of mental disorders caused by cerebral vascular diseases in the elderly. Methods 104 patients with mental disorders caused by cerebrovascular disease treated at our hospital from December, 2015 to March, 2018 were selected, and were divided into an observation group (n=52) and a control group (n=52) using the random number table method. The control group were treated with olanzapine, and the observation group with magnesium valproate sustained-release tablets and olanzapine, for 8 weeks. The treatment effect and incidence of adverse reactions were compared between these two groups. Results After 8 weeks’ treatment, the total effective rate was 84.62% in the observation group, and was 67.31% in the control group (P 0.05). Conclusion Magnesium valproate sustained release tablets combined with olanzapine in the treatment of elder patients with mental disorders caused by cerebral vascular diseases is effective and safe. Key words: Mental disorders induced by cerebrovascular disease; Olanzapine; Magnesium valproate sustained-release tablets
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
